UnitedHealth (UNH) Stock Falls as Much as 4.7%, Testing Its 50-Day Average as Health Insurers Slide
Key Takeaways
- •UNH shares dropped as much as 4.7% on Tuesday to an intraday low of $389.50, falling below the 50-day moving average at $391.36, as part of a broader managed care selloff that also weighed on Humana and CVS.
- •UnitedHealth reported third-quarter earnings of $4.69 per share on Oct. 13, beating the $4.14 estimate, with revenue of $112.72 billion topping the $111.31 billion expected, and set a 2026 earnings floor of $20.50 per share or better.
- •Sector pressure centers on Medicare Advantage reimbursement rates and rising medical costs, leaving managed care margins sensitive to annual reimbursement decisions and utilization trends.
- •Wall Street leans positive on UNH with twenty Buy and eight Hold ratings and an average price target of $463.93, though Wells Fargo lowered its target to $487 on Oct. 27 while JPMorgan raised its target to $524 on Oct. 16.
- •Institutional flows showed accumulation, including Intech Investment Management boosting its stake 36.8% in the third quarter and $86.8 million in net ETF buying on Nov. 11, while CEO Patrick Conway sold $455,910 worth of shares on Aug. 21.

Shares of UnitedHealth Group Incorporated (NYSE: UNH) came under pressure in morning trading on Tuesday, falling as much as 4.7% and touching an intraday low of $389.50 — well below Monday's close of $412.02. The move formed part of a broader decline across managed care, with Humana and CVS also trading lower.
Health insurers were weak from the outset: UNH was down about 2.8% in premarket trading alongside Humana and CVS. The session low then landed just beneath a closely watched technical level — the stock's 50-day moving average, which sits at $391.36. Levels like this are tracked by traders as a gauge of whether a stock's medium-term momentum is holding, which is why an intraday test of the line tends to draw attention even in the absence of company-specific news.
The weakness came amid a modestly lower open for U.S. equities. The S&P 500 opened down 0.2%, the Dow lost 0.4%, and the Nasdaq slipped 0.2%. Traders were also awaiting Nvidia's earnings and weighing new U.S. limits on AI chip exports — a macro backdrop that framed the session for the managed care group as well.
What Is Weighing on Managed Care
Medicare Advantage reimbursement and rising medical costs have kept the managed care group under a microscope in recent months. Medicare Advantage — government-funded health coverage administered by private insurers — sits at the center of UnitedHealth's benefits business, so sector margins are sensitive to annual reimbursement rates on one side and utilization and cost trends on the other. Investing.com reported that the pressure on the sector intensified on Tuesday.
Recent analyst actions have pointed in different directions. Wells Fargo trimmed its price target on UNH from $526 to $487 on Oct. 27 while keeping an overweight rating on the shares. JPMorgan, by contrast, raised its target from $516 to $524 on Oct. 16.
Overall, the Street leans positive: twenty analysts rate the stock a Buy and eight a Hold, with an average price target of $463.93.
The Numbers Behind the Stock
UnitedHealth posted third-quarter earnings of $4.69 per share on Oct. 13, topping the $4.14 estimate. Revenue came in at $112.72 billion, ahead of the $111.31 billion expected. The company also set its 2026 earnings floor at $20.50 per share or better — a fundamental backdrop that traders on Tuesday were weighing against the sector's persistent cost pressures.
Even after Tuesday's decline, the stock remains far above its 12-month low of about $256. Its 12-month high stands at $461.62.
Within the quarter, Optum Rx, the company's pharmacy services arm, grew operating earnings even as prescription volumes came in lower, with increased biosimilar use and cost savings providing support.
Institutional buyers have also shown up recently. MarketBeat reported that Intech Investment Management raised its UNH stake by 36.8% in the third quarter, adding 56,872 shares to reach 211,490 in all. On Nov. 11, 51 ETFs bought the stock while nine sold, amounting to $86.8 million in net buying — the kind of positioning data market watchers use to gauge how professional money is responding to the sector's swings.
Insider activity, however, moved the other way: CEO Patrick Conway sold $455,910 worth of stock at $390 per share on Aug. 21, cutting his holdings by 7.09%.
Dividend and Technical Picture
UnitedHealth's next quarterly dividend of $2.32 per share is scheduled to be payable on Dec. 15 to stockholders of record as of Dec. 7, a payout that works out to a yield of roughly 2.3% and the nearest scheduled company event on the calendar.
One technical reading characterizes UNH as a stock in consolidation, with neutral momentum and thin trading volume — a combination that points to no strong near-term directional signal from market activity. With the session low probing beneath the 50-day average, that level now stands as the most immediate reference point for the stock's short-term trend.